



Hepatitis C (Acute, Chronic, Perinatal)

02/10/2025

DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS

Cases should be reported to the local health department where the patient resides. If patient residence is unknown, report to your own local health department. Contact information is available at: <http://localhealth.nj.gov>.

If the individual does not live in New Jersey, report the case to the New Jersey Department of Health at: (609) 826-5964.

In cases of immediately reportable diseases or other emergencies – if the local health department cannot be reached – the New Jersey Department of Health maintains an emergency after-hours phone number at: (609) 392-2020.

1 THE DISEASE AND ITS EPIDEMIOLOGY

A. Etiologic Agent

Hepatitis C is a liver infection caused by the blood-borne hepatitis C virus (HCV). HCV is an enveloped RNA virus of the genus *Hepacivirus* in the Flaviviridae family, with seven distinct genotypes identified. Genotype 1 is the most common HCV genotype in the United States.

B. Clinical Description and Laboratory Diagnosis

Hepatitis C is a disease with varying rates of progression. In general, its course is slowly progressive. For people with recent (acute) HCV infection, only about 20-30% will experience symptoms. Therefore, it is uncommon for people to be diagnosed with hepatitis C infection in the acute stage. For people with acute HCV infection, when symptoms do occur, they may include fatigue, fever, nausea, vomiting, jaundice, abdominal pain, loss of appetite, dark urine, clay-colored stools, joint pain. The average time from exposure to symptoms ranges from 2 to 12 weeks <https://www.cdc.gov/hepatitis-c/about/index.html>.

Most people with chronic HCV do not have any symptoms or may have common symptoms such as chronic fatigue and depression. Of those chronically infected, about 5-25% may eventually develop cirrhosis within 10-20 years. Cirrhosis can lead to liver failure or liver cancer. Factors related to developing cirrhosis include alcohol consumption, being male, age 50 years and older, co-infection with hepatitis B virus, nonalcoholic fatty liver disease or HIV, or receive immunosuppressive drugs. Approximately 50% of people who test anti-HCV positive do not have current chronic infection which indicates that they may have experienced spontaneous clearance after acute infection.

- **Pregnant women:** The CDC recommends that all pregnant women be routinely screened for HCV during each pregnancy. <https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html#>. The rate of HCV transmission from a pregnant woman to their child is estimated to be 6-7% but can be as high as 11% if the pregnant woman is also coinfecting with HIV. <https://www.cdc.gov/mmwr/volumes/72/rr/pdfs/rr7204a1-H.pdf>.
- **Perinatal exposure:** In 2023, CDC released recommendations for hepatitis C testing among perinatally exposed infants and children. These new recommendation for testing and management of perinatally exposed infants and children promotes early diagnosis and linkage to care for this vulnerable group. There are four components to the recommendations:
 1. HCV testing of all perinatally exposed infants with a nucleic acid test (NAT) for detection of HCV RNA at age 2-6 months.
 2. consultation with a health care provider with expertise in pediatric hepatitis C management for all infants and children with detectable HCV RNA.
 3. perinatally exposed infants and children with an undetectable HCV RNA result after age 2 months do not require further follow up unless clinically warranted.
 4. a NAT for HCV RNA is recommended for perinatally exposed infants and children aged 7-17 months who previously have not been tested, and a hepatitis C virus antibody (anti-HCV) test followed by a reflex NAT for HCV RNA (when anti-HCV is reactive) is recommended for perinatally exposed children aged > 18 months who previously have not been tested. Proper identification of perinatally infected children, referral to care, and curative treatment are critical to achieving the goal of hepatitis C elimination.

The siblings of children with vertically acquired chronic HCV should be tested for HCV infection, if born from the same mother. <https://www.hcvguidelines.org/unique-populations/children>.

Clinical screening

Laboratory diagnosis is based upon several blood tests which include:

- I. Screening tests for antibody to HCV (anti-HCV): enzyme immunoassay (EIA), enhanced chemiluminescence immunoassay (CIA)
- II. Qualitative tests to detect presence or absence of virus: HCV RNA polymerase chain reaction (PCR), HCV Genotype
- III. Quantitative tests to detect amount (titer) of virus: HCV RNA PCR.

The Centers for Disease Control and Prevention (CDC) produced an algorithm that outlines the testing process for HCV diagnosis https://www.cdc.gov/hepatitis/hcv/pdfs/hcv_flow.pdf as well as a table which interprets the different tests for HCV infection https://www.cdc.gov/hepatitis/hcv/pdfs/hcv_graph.pdf. HCV infection can be detected by anti-HCV on average 8–11 weeks after infection, but cases of seroconversion may be delayed in people who are immunosuppressed. HCV RNA can be detected in blood as early as 1–2 weeks after infection <https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html>.

Possibility of false positive and negative

False-positive anti-HCV test results may occur when people at low risk for HCV infection (e.g., blood donors) are tested. All positive anti-HCV tests should be followed by an RNA test to establish current infection. False-negative anti-HCV test results may occur in people with early HCV infection who have not yet developed antibody levels high enough to be detectable with testing. Additionally, some people might not mount a sufficient immune response to have detectable antibody levels. In these people, further testing with an HCV RNA test is recommended.

Treatment

Over 90% of people infected with hepatitis C virus (HCV) can be cured of their infection, with 8–12 weeks of oral therapy regardless of HCV genotype. To provide health-care professionals with timely guidance as new therapies are available and integrated into hepatitis C treatment regimens, the Infectious Diseases Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD), in collaboration with the International Antiviral Society–USA (IAS–USA), developed evidence-based, expert-developed recommendations for hepatitis C management. These recommendations are available at <http://www.hcvguidelines.org/>.

C. Reservoirs

Infected humans are the only known source of this disease.

D. Modes of Transmission

HCV is predominantly spread person-to-person via parenteral exposure to contaminated blood or blood products. Currently, the most prevalent mode of transmission is through the use of contaminated needles, syringes and other instruments used for injections and other skin-piercing procedures <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Before screening for HCV became available in 1992, it was commonly spread through blood transfusions and organ transplants. Screening has significantly reduced unintended transmission via these sources.

Other potential risks for transmission include:

- Vertical transmission - infected mother to infant
- Other health-care procedures that involve invasive procedures, such as injections, hemodialysis
- Accidental needlestick injuries in health care settings
- Tattooing or body piercing with non-sterilized equipment

- Sharing straws for intranasal cocaine use
- Sharing personal items contaminated with infectious blood, such as razors or toothbrushes
- Household or sexual contacts with HCV-infected persons

HCV is not spread by casual contact, kissing, sneezing, hugging, sharing glasses or utensils, food, water, or breast milk.

E. Incubation Period

The incubation period for HCV ranges from 2 weeks to 6 months, with an average of 14-84 days.

<https://www.cdc.gov/hepatitis/resources/professionals/pdfs/abctable.pdf>

F. Period of Communicability or Infectious Period

Persons newly infected with HCV are generally infectious 1 or more weeks before the onset of the first symptoms; infectivity may persist indefinitely.

G. Epidemiology

Hepatitis C has a worldwide distribution. Globally, an estimated 50 million people have chronic hepatitis C infection <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>.

In the United States an estimated 2.4 million people, 1 % percent of the adult population, were living with hepatitis C from 2013–2016 <https://pubmed.ncbi.nlm.nih.gov/38739849/>. During 2022, 46 states and the District of Columbia reported a total of 4,848 acute hepatitis C cases corresponding to 67,400 estimated acute hepatitis C virus (HCV) infections. The number of acute hepatitis C cases in 2022 was 2 times as high as in 2015. HCV infection occurs among all demographic groups. Although the rate of acute hepatitis C among non-Hispanic White persons decreased during 2021–2022, the rate among non-Hispanic AI/AN persons increased by 7.4% and was 1.9 times as high as the rate among non-Hispanic White persons. During 2022, rates of acute hepatitis C were highest among males, persons aged 30–39 years, and those living in the Eastern and Southeastern states. Among cases with risk information reported, the most common was injection drug use <https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-c/index.html>.

In New Jersey, the estimated number of persons infected with HCV is roughly 680/100,000 people (2013-2016) <https://hepvu.org/local-data/new-jersey/>. In 2022, most of the newly diagnosed cases in New Jersey were persons with newly reported chronic HCV (4,674), rather than acute HCV infection (68), with 40% male. The highest prevalence of cases occurred among persons 30 to 40 years and 55 to 70 years. The highest incidence of acute HCV occurred among persons who inject drugs.

2 CASE DEFINITIONS

New Jersey Department of Health (NJDOH) follows the CDC's 2020 updated case definitions for acute and chronic hepatitis C as well as the new 2018 perinatal HCV case definition.

A. Acute Hepatitis C

<https://ndc.services.cdc.gov/case-definitions/hepatitis-c-acute-2020/>

i. Clinical Criteria:

One or more of the following:

- Jaundice

OR

- Peak elevated total bilirubin levels ≥ 3.0 mg/dL

OR

- Peak elevated serum alanine aminotransferase (ALT) levels >200 IU/L

AND

The absence of a more likely diagnosis (which may include evidence of acute liver disease due to other causes or advanced liver disease due to pre-existing chronic Hepatitis C virus (HCV) infection or other causes, such as alcohol exposure, other viral hepatitis, hemochromatosis, etc.).

ii. Laboratory Criteria:

Probable laboratory evidence

- A positive test for antibodies to hepatitis C virus (anti-HCV)

Confirmatory laboratory evidence

- Positive hepatitis C virus detection test: Nucleic acid test (NAT) for HCV RNA positive (including qualitative, quantitative or genotype testing)

OR

- A positive test indicating presence of hepatitis C viral antigen(s) when available¹.

iii. Epidemiologic Linkage

No epidemiologic linkage is required for case classification.

iv. Case Classification:

Probable

- A case that meets clinical criteria and has presumptive laboratory evidence,
AND
- Does not have a hepatitis C virus detection test reported,
AND
- Has no documentation of anti-HCV or HCV RNA test conversion within 12 months,

Confirmed

- A case that meets clinical criteria and has confirmatory laboratory evidence,
OR
- A documented negative HCV antibody followed within 12 months by a positive HCV antibody test (anti-HCV test conversion) in the absence of a more likely diagnosis,
OR
- A documented negative HCV antibody OR negative hepatitis C virus detection test (in someone without a prior diagnosis of HCV infection) followed within 12 months by a positive hepatitis C virus detection test (HCV RNA test conversion) in the absence of a more likely diagnosis.

Note: A new probable acute case should be re-classified as confirmed acute case if a positive NAT for HCV RNA or a positive HCV antigen(s) test is reported within 12 months. A new confirmed chronic case should be created if a positive HCV RNA NAT or HCV antigen is reported one year or more after acute case onset. A new probable chronic case (i.e., anti-HCV positive, but with an unknown HCV RNA NAT or antigen status) should not be created following a confirmed acute case because of previous HCV RNA NAT reported. Report acute cases by date of diagnosis (Illness onset date). Illness onset date should not be reported for chronic cases. All hepatitis C virus cases in each classification category should be > 36 months of age, unless known to have been exposed non-perinatally.

¹ When and if a test for HCV antigen(s) is approved by the FDA and available.

B. Chronic Hepatitis C

<https://ndc.services.cdc.gov/case-definitions/hepatitis-c-chronic-2020/>

i. Clinical Criteria

No available evidence of clinical and relevant laboratory information indicative of acute infection. Most HCV infected persons are asymptomatic; however, many have chronic liver disease, which can range from mild to severe.

ii. Laboratory Criteria for Diagnosis

Probable laboratory evidence

- A positive test for antibodies to hepatitis C virus (anti-HCV)

Confirmatory laboratory evidence

- Positive hepatitis C virus detection test: Nucleic acid test (NAT) for HCV RNA positive (including qualitative, quantitative, or genotype testing),
OR
- A positive test indicating presence of hepatitis C viral antigen(s) (HCV antigen).

iii. Epidemiologic Linkage

No epidemiologic linkage is required for case classification.

iv. Case Classification

Probable

- A case that does not meet the clinical criteria or has no report of clinical criteria.
AND
- Does not have a documented negative HCV antibody, HCV antigen or NAT laboratory test result followed within 12 months by a positive result of any of these tests (test conversion) or has no report of test conversion.
AND
- Has a positive anti-HCV antibody test, but no report of a positive HCV NAT or positive HCV antigen test.

Confirmed

- A case that does not meet the clinical criteria or has no report of clinical criteria.
AND
- Does not have a documented negative HCV antibody, HCV antigen or NAT laboratory test result followed within 12 months by a positive result of any of these tests (test conversion) or has not report of test conversion.
AND
- Has a positive HCV NAT or HCV antigen test (may have any anti-HCV antibody test result).

C. Perinatal Hepatitis C

<https://ndc.services.cdc.gov/case-definitions/hepatitis-c-perinatal-infection-2018/>

i. Clinical Criteria

Perinatal hepatitis C in pediatric patients may range from asymptomatic to fulminant hepatitis.

ii. Laboratory criteria for diagnosis

- HCV RNA positive test results for infants between 2 to 36 months of age.
OR
- HCV genotype test results for infants between 2 to 36 months of age.
OR
- HCV antigen¹ test results for infants between 2 to 36 months of age.

iii. Epidemiologic Linkage

Maternal infection with HCV of any duration, if known. Not known to have been exposed to HCV via a mechanism other than perinatal (e.g. not acquired via healthcare).

**iv. Case Classification
Confirmed**

Infant who has a positive test for HCV RNA nucleic acid test (NAT), HCV antigen, or detectable HCV genotype at ≥ 2 months and ≤ 36 months of age and is not known to have been exposed to HCV via a mechanism other than perinatal.

Note: Test results prior to 2 months of age should not be used for classification. Test results after 36 months of age should be reported under the **2020** Acute and Chronic HCV Infection case classification and not as perinatal HCV infection. Cases in the specified age range that are known to have been exposed to HCV via healthcare and not perinatally should be reported under the **2020** position statement. All hepatitis C virus cases in each classification category should be > 36 months of age, unless known to have been exposed non-perinatally.

D. Case Classification Summary

After investigation of a reported Hepatitis C case has been completed the case should be assigned a Disease Group and Case Status as shown in Table 1.

Table 1. HCV Case Classification Assignments

Is there an HCV antibody result?	Is there a positive HCV RNA NAT OR Genotype reported?	Are there signs of acute infection or documentation of seroconversion? *	HCV Disease Subgroup	HCV Case Status	Further Actions
Positive, Negative or not reported	Yes- Positive	Yes	Acute	Confirmed	Provide appropriate counseling and linkage to care
Positive or not reported	Yes- Positive	No or Unknown	Chronic	Confirmed	Provide appropriate counseling and linkage to care
Yes positive result is the only HCV test reported	Unknown/Not reported	Yes	Acute	Probable	Recommend testing for HCV RNA to identify current infection
Yes positive result is the only HCV test reported	Unknown/Not reported	No or Unknown	Chronic	Probable	Recommend testing for HCV RNA to identify current infection
Positive, Negative or not reported	Negative/Not Detected or Below level of detection	Yes, No or Unknown	Pending	Not a Case	No further action required in most cases. Further testing may be recommended for ongoing risk exposures
< 36 months of age Positive or not reported	Yes- Positive	No	Perinatal	Confirmed	Recommend referral to a pediatric specialist for further management
< 36 months of age Positive or not reported	Negative/Not Detected or Below level of detection	No	Perinatal	Not a Case	No further action required

* ALT>200 and/or Bili>3 or report of jaundice with no other explanation or documentation of prior negative result within the past 12 months.

3 LABORATORY TESTING

The NJDOH Public Health and Environmental Laboratories (PHEL) do not provide routine HCV antibody testing. Testing is widely available at clinical and commercial laboratories. Molecular sequencing (genetic typing) may be performed in response to an outbreak after consultation with NJDOH Communicable Disease Service (CDS) staff.

4 PURPOSE OF SURVEILLANCE AND REPORTING REQUIREMENTS

A. Purpose of Surveillance and Reporting

1. To identify persons infected with HCV to ensure that they are educated on the need for medical evaluation to reduce disease progression and to provide referrals to support services.
2. To identify cases and determine the incidence and prevalence of HCV in specific populations and geographic locations to better inform HCV prevention and service activities.
3. To provide information to persons infected with HCV on how to prevent exposing others.
4. To identify outbreaks.
5. To identify new risk factors for transmission of HCV.

B. Laboratory and Healthcare Provider Reporting Requirements

NJAC 8:57-1 et seq. stipulates that laboratories and healthcare providers must report by telephone, confidential fax, over the Internet using the confidential and secure Communicable Disease Reporting and Surveillance System (CDRSS), or in writing, all suspected cases of newly diagnosed acute illness of hepatitis C and newly diagnosed chronic cases of HCV within 24 hours of diagnosis to the NJDOH Infectious and Zoonotic Diseases Program (IZDP) at 609.826.5964 or fax 609.826.5821.

<https://www.nj.gov/health/cd/reporting/acode/>

The report shall contain the reporting laboratory's name, address, and telephone number; the first name, last name, age, date of birth, sex, race, ethnicity, home address and telephone number of the person tested; the test performed; the source or type of specimen tested, the date the specimen was collected, and the date of testing; the test results; and the healthcare provider's name, address, and telephone number.

Note: If a healthcare provider is reporting, ask him or her to inform the patient that someone from the local health department will be contacting the patient for follow-up.

C. Local Department of Health Reporting Requirements

NJAC 8:57-1 et seq. stipulates that each local health officer must report the occurrence of any suspected case of HCV. Case reports received by a local health department should be reported to NJDOH, IZDP electronically via the Internet using CDRSS. Most HCV reports will go directly to NJDOH from labs/healthcare providers, but some may continue to go to the local health department.

5 CASE INVESTIGATION

A. Forms and Laboratory Reports

A positive hepatitis C test (HCV antibody; HCV RNA NAT, including genotype) reported electronically into CDRSS or directly to the local health department (LHD) is the primary trigger for investigation of a new case. The LHD should utilize the NJDOH CDS-17 Form. <https://www.nj.gov/health/forms/cds-17.pdf> to collect case information. The LHD's initial goal is to determine if the case is Acute or Chronic hepatitis C. To guide this case classification, the following steps should be taken on all HCV disease reports received. Note: if the case has been previously reported to CDRSS and closed as a confirmed case no further investigation is required. To merge a new case to a confirmed chronic case, reference NJDOH's case merge document [CDRSS || CDRSS HELP DOCUMENTS & USER GUIDES](#). To reduce the investigation load for the jurisdictions which receive a huge number of HCV disease reports NJDOH classifies cases into priority and non-priority groups.

1. The NJDOH hepatitis C identified priority groups are as follows:

- All cases 40 years of age and younger.
- All cases suspected to be acute: that is, with evidence of jaundice, Bili ≥ 3 mg/dl, ALT ≥ 200 U/L, and absence of more likely diagnosis.
- All cases suspected to be a seroconversion: that is, positive HCV test within 12 months of a documented negative HCV test.
- All cases with a healthcare associated risk factor: hemodialysis, invasive medical procedures, healthcare worker, blood, organ, or tissue transplant.
- All pregnant women and perinatal cases

Priority groups investigation steps

- I. The LHD should make two attempts to collect information on the CDS- 17 form from the provider who ordered the hepatitis C test(s). This attempt can be made via phone, fax, email, or letter and should be documented in the comments section of CDRSS. Information returned on the form should be entered in CDRSS, as well. Ideally these two attempts should be at least a week apart and within the first 30 days after the case was reported.
- II. If the attempt to reach the provider is not successful, LHD should make two attempts to collect information directly from the patient. These attempts can be done via phone or letter. These attempts should also be documented in CDRSS. Ideally attempts to reach the patient should be done at least a week after provider contact. Each contact to the patient should be at least a week apart and conducted no later than 60 days after the case was initially reported. Reassure the patient that all information is kept strictly confidential.
- III. If a response is not received from the physician or patient after all attempts, a final letter should be sent to the patient asking him/her to contact the health department with the requested information. Reference the NJDOH [HCV letter template](#). This letter may not be feasible for those located within an institution. In these cases, LHD can skip this step and proceed with case classification per the [HCV Case Classification Algorithm](#) or [Hepatitis C Perinatal Case Classification Algorithm](#) for perinatal cases.
- IV. Contact the referring medical facility for additional information if the case is suspected to be acute as

additional information is needed to confirm classification.

- V. Cases determined to have a reported positive hepatitis C serology test within 12 months of a documented negative HCV test (i.e., seroconversion) and/or has a health care associated risk factor will need additional investigation and follow up. See below under Healthcare Associated Infection (HAI).
 - VI. If no response to any attempt is received within 30 days of sending this final letter, the case should be closed based on existing information in CDRSS per the HCV Case Classification Algorithm or Hepatitis C Perinatal Case Classification Algorithm for perinatal cases.
2. **The NJDOH hepatitis C identified non-priority groups are as follows:**
Cases older than 40 years of age that do not meet the criteria for acute illness or seroconversion, are not healthcare associated, and are not associated with a pregnancy.

Non-priority groups investigation steps

- I. The LHD should make a single attempt to collect information on the CDS-17 from the provider who ordered the testing. This attempt can be made via phone, fax, email, or letter and should be documented in the comments section of CDRSS. Information returned on the form should be entered in CDRSS. Based on information received the case should be classified appropriately in CDRSS per the HCV Case Classification Algorithm. The case should be classified appropriately in CDRSS, based on the information received.
- II. Contact the referring medical facility for additional information if the case is suspected to be acute (i.e., determined to have either signs and symptoms, or ALT>200 IU/L) as additional information is needed to confirm classification.
- III. Cases determined to have a reported positive hepatitis C serology test within 12 months of a documented negative HCV test (i.e., seroconversion) and/or has a health care associated risk factor (hemodialysis, invasive medical procedures, healthcare worker, blood, organ, or tissue transplant) will need additional investigation and follow up. See below under Healthcare Associated Infection (HAI).

A. Entry into CDRSS

The mandatory fields to be populated in CDRSS include disease, first name, last name, birth date, county, municipality, gender, race, ethnicity, case status, and report status.

The following table can be used as a reference guide to determine which fields need to be completed for accurate and complete reporting of HCV. The “Tab” column includes the tabs that appear along the top of the CDRSS screen. The “Required Information” column provides detailed explanations of what data should be entered.

Table 2. Critical CDRSS Fields to be completed.

CDRSS Fields	Required Information
Disease Information (a): Disease, Subgroup, Report/Illness Onset Date	<ul style="list-style-type: none"> Select the appropriate SUBGROUP based on the appropriate classification after investigation is complete. Reference section 2A above. <ul style="list-style-type: none"> Select “Pending” for all new reports for persons >36 months old and “Perinatal” for persons <36 months old.
Disease Information (b): Case Status, Report Status (see next section for perinatal assignment)	<ul style="list-style-type: none"> Upon completion of the investigation, “Confirmed” “Probable”, and “Not a Case” are the only appropriate options for classifying a case of HCV. Reference section 2A above. Be sure to indicate “Seroconversion” under Reason for Status if the case is classified Acute Confirmed based on test conversion.
Comments	<p>Enter details here related to the investigation progress or that is not discretely captured by a specific topic screen or drop-down menu.</p> <p>NOTE: It is important not to put information here which should be captured under other sections, for example risk factors. Information in this section cannot be queried for a report</p>
Clinical Status	<ul style="list-style-type: none"> In the drop-down next to REASON FOR TESTING, select the appropriate choice, for e.g. “Symptoms of Acute Hepatitis”. In the drop-down next to PRE-EXISTING CONDITIONS, select the appropriate choice, for e.g. “Chronic Renal Disease”. Enter any other known clinical information here as indicated by the drop downs.
Risk Factors	<ul style="list-style-type: none"> An attempt should be made to identify risk factors for all acute and chronic cases, especially acute cases. Reference the CDS-17 Form and CDRSS as a guide.
Treatment Information	<ul style="list-style-type: none"> Use the drop-down next to TREATMENT to select the name of the HCV medication that the person is receiving or has received. Enter as much information as known about PRESCRIBING PHYSICIAN NAME, ORDERING FACILITY, TREATMENT DATES. Dosage, frequency, and any other treatment related information can be added to the text box. If the text box is used, check FREE-TEXT INPUT.

B. Other Reporting/Investigation Issues

1. Case report forms DO NOT need to be mailed to NJDOH if mandatory fields indicated in section 5B are completed in CDRSS.
2. Once an LHD completes its investigation and assigns a report status of “LHD CLOSED,” NJDOH will review the case. NJDOH will approve the case by changing the report status to “DHSS APPROVED.” At this time, the case will be submitted to the CDC and the case will be locked for editing. If additional information is received after a case has been placed in “DHSS APPROVED,” LHDs will need to contact NJDOH to reopen the case. This should be done only if the additional information changes the case status of the report
3. Every effort should be made to complete the investigation within three months of case receipt.

6 CONTROLLING FURTHER SPREAD

A. Isolation and Quarantine

i. Minimum Period of Isolation of Patient

No restrictions except for exclusion from blood donation and counseling to modify activities to prevent transmission.

ii. Minimum Period of Quarantine of Contacts

None.

B. Protection of Contacts of a Case

Standard precautions for cases are recommended to prevent exposing others to blood and body fluids. Immunoglobulin prophylaxis is not effective and is not recommended for contacts of persons who are infected with HCV.

C. Managing Special Situations

There are no specific regulations regarding HCV infection in daycare, school, or community residential programs. HCV is not spread via casual contact or through food or water. Provided standard precautions are maintained, HCV will not be spread to others in these settings. No person who is infected with HCV should be excluded from attending or working in any of these settings based on his/her HCV infection.

Correctional Facility Investigations

The institutions in New Jersey which house confined inmates are mainly Federal, State and County facilities. HCV disease reports are frequently received from these institutions.

Per NJAC 8:57 regulation, state institutions are required to report communicable diseases directly to NJDOH. State Correctional Facility cases are investigated by the contracted care group for state facilities. Prison and jail facilities have procedures in place to notify LHDs when a prisoner is released into their jurisdiction with a communicable disease. Once an inmate is released and has been relocated into the LHD's jurisdiction, the LHD now has an obligation to conduct additional investigations, if necessary.

The LHD is responsible for investigating all non-state prison and jail facilities cases. Investigate as per priority or non-priority group as explained above.

Hemodialysis

Patients requiring hemodialysis are at high risk for infection because the process of hemodialysis requires frequent use of catheters or insertion of needles to access the bloodstream https://www.cdc.gov/dialysis-safety/about/?CDC_AAref_Val=. In an environment where multiple patients receive dialysis concurrently, repeated opportunities exist for person-to-person transmission of infectious agents, directly or indirectly via contaminated devices, equipment and supplies, environmental surfaces, or hands of personnel.

Furthermore, hemodialysis patients have weakened immune systems, which increase their risk for infection, and they require frequent hospitalizations and surgery which increases their opportunities for exposure to healthcare associated infections. To reduce transmission of infectious agents, dialysis centers in New Jersey routinely tests patients undergoing chronic dialysis and have been proactive about reporting seroconversion and working with public health officials to determine where breaches may have occurred.

If an HCV case investigation reveals the patient is a current or past recipient of dialysis, this should be documented in the CDRSS record. Investigation should include date of admission to dialysis facility and HCV status upon admission. LHD should contact NJDOH to determine if a more in-depth investigation is required.

Organ Transplant

The availability of and high cure rate associated with direct-acting antiviral agents (DAA) has made the use of HCV positive organ transplantation more widely accepted. This has increased the number of organs available for transplant and shortened the wait time for many needing lifesaving transplants <https://www.hcvguidelines.org/unique-populations/organs-from-hcv-viremic-donors>. There are some indicators that would signal a transplant case. They include ordering facility is a transplant facility, ordering provider is associated with a transplant facility, documented evidence of seroconversion, increased frequency of HCV lab values. If a new HCV case appears to be associated with transplant, investigation is needed to determine date of transplant, organ transplanted and plans for treatment of HCV post-transplant. Further public health investigation is not indicated. The case would be classified as Disease Subgroup: Acute and Case Status: Confirmed

Injection Safety/Breaches

Injected medicines are commonly used in healthcare settings for the prevention, diagnosis, and treatment of various illnesses. Unsafe injection practices put patients and healthcare providers at risk of infectious and non-infectious adverse events and have been associated with a wide variety of procedures and settings.

If an HCV case investigation reveals the patient has had significant medical procedures with no traditional HCV risk factors, this should be documented in the CDRSS record. LHD should contact NJDOH to determine if a more in-depth investigation is required.

D. Preventive Measures

The role of the local health department in managing HCV largely is educating persons who are infected on how to care for themselves and avoid spreading infection to others. Prevention and education include information on how the disease is transmitted, how to avoid transmitting to others, and how infected persons can protect themselves from other potential sources of liver damage.

Offer the following information and support to HCV infected persons/cases:

- Provide basic instruction on transmission of HCV and emphasize the need for ongoing medical evaluation. The person should be referred to their healthcare provider for treatment options.
- Educate on the need to completely abstain from alcohol to help protect the liver. If the person needs or wants support to stop drinking, provide referrals to appropriate treatment or support services.
- Discuss medications that should be avoided (e.g. acetaminophen) as high doses of these can damage the liver. Infected persons should discuss any medications (including over-the-counter medications) and dietary supplements and herbs with a healthcare provider before taking them to be certain the medications will not impair liver function.
- Provide information on the importance of hepatitis A and B immunization. Refer to the NJDOH Hepatitis A and Hepatitis B Chapters https://www.state.nj.us/health/cd/topics/hepatitis_viral.shtml.
- Discuss sexual transmission of HCV. Indicate that HCV may be transmitted during sex, but that the risk is low. All contact with blood during sex should be avoided. Emphasize latex barrier protection to prevent the spread of HCV, as well to prevent the exposure to, and transmission of other pathogens.

- Discuss household transmission of HCV. Household transmission is rare, but to ensure that it does not happen, the person should not share razors, toothbrushes, nail clippers, or any other item that could be contaminated with blood.
- Inform the person that they should not be restricted from working, preparing food, or taking part in their daily activities unless they have specific symptoms that make it difficult to do so.
- There are no recommendations suggesting that persons who are infected with HCV change their exercise routines or have any dietary restrictions other than avoidance of alcohol.

7 ADDITIONAL INFORMATION

Supporting Hepatitis C documents and resources can be obtained from the New Jersey Department of Health website Hepatitis C page <https://www.state.nj.us/health/cd/topics/hepatitisc.shtml>.

References

American Association for the Study of Liver Diseases. (2022, October 24). *HCV in Children*. Retrieved from Unique & Key Populations: <https://www.hcvguidelines.org/unique-populations/children>

American Association for the Study of Liver Diseases. (2023, December 19). *Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors*. Retrieved from Unique & Key Populations: <https://www.hcvguidelines.org/unique-populations/organs-from-hcv-viremic-donors>

American Association for the Study of Liver Diseases. (2023). *Welcome to HCVGuidelines.org*. Retrieved from HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C: <https://www.hcvguidelines.org/>

Centers for Disease Control and Prevention. (2021, April 16). *Hepatitis C Acute 2020 Case Definition*. Retrieved from National Notifiable Diseases Surveillance System (NNDSS): <https://ndc.services.cdc.gov/case-definitions/hepatitis-c-acute-2020/>

Centers for Disease Control and Prevention. (2021, April 16). *Hepatitis C Chronic 2020 Case Definition*. Retrieved from National Notifiable Diseases Surveillance System (NNDSS): <https://ndc.services.cdc.gov/case-definitions/hepatitis-c-chronic-2020/>

Centers for Disease Control and Prevention. (2021, April 16). *Hepatitis C Perinatal Infection 2018 Case Definition*. Retrieved from National Notifiable Diseases Surveillance System (NNDSS): <https://ndc.services.cdc.gov/case-definitions/hepatitis-c-perinatal-infection-2018/>

Centers for Disease Control and Prevention. (2023, November 3). *CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children — United States, 2023*. Retrieved from Morbidity and Mortality Weekly Report: [chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.cdc.gov/mmwr/volumes/72/rr/pdfs/rr7204a1-H.pdf](https://www.cdc.gov/mmwr/volumes/72/rr/pdfs/rr7204a1-H.pdf)

Centers for Disease Control and Prevention. (2023, December 19). *Clinical Screening and Diagnosis for Hepatitis C*. Retrieved from Hepatitis C: <https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html#>

Centers for Disease Control and Prevention. (2024, October 9). *Hepatitis C Surveillance*. Retrieved from 2022 Viral

Hepatitis Surveillance Report: <https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-c/index.html>

Centers for Disease Control and Prevention. (2024, March 26). *Infections and Patients on Dialysis*. Retrieved from Dialysis Safety: https://www.cdc.gov/dialysis-safety/about/?CDC_AAref_Val=

Centers for Disease Control and Prevention. (2025, January 31). *Hepatitis C*. Retrieved from Hepatitis C Basics: <https://www.cdc.gov/hepatitis-c/about/index.html>

New Jersey Department of Health . (2024, May 13). *Viral Hepatitis*. Retrieved from Communicable Disease Service: https://www.nj.gov/health/cd/topics/hepatitis_viral.shtml

New Jersey Department of Health. (2017, April 5). *NJ Administrative Code*. Retrieved from Communicable Disease Service: <https://www.nj.gov/health/cd/reporting/acode/>

New Jersey Department of Health. (2024, November 15). *For The Community*. Retrieved from Local Public Health: <https://www.nj.gov/health/lh/community/index.shtml#1>


New Jersey Department of Health. (2025, February 03). *Hepatitis C*. Retrieved from Communicable Disease Service: <https://www.state.nj.us/health/cd/topics/hepatitisc.shtml>

World Health Organization. (2024, April 09). *Hepatitis C*. Retrieved from Newsroom: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>

8

APPENDICES


A. HCV Case Classification Algorithm



*When and if a test for HCV antigen(s) is approved by the FDA and available

B. Perinatal Hepatitis C Case Classification Algorithm

Hepatitis C Perinatal Case Classification Algorithm
For infants between 2 months and 36 months of age



- ❖ If the infant is less than 2 months of age with positive HCV test, the recommendation is that a confirmatory test be repeated between 2 months and 36 months of age.
- ❖ For cases, older than 36 months of age the standard Hep C investigation procedure should be followed.

C. Interpretation of Laboratory Test Names in CDRSS

CDRSS Test Name	Test Type
Hepatitis C Virus Antibody (Anti-HCV)	Antibody test
Hepatitis C Virus Antibody Signal to Cut Off Ratio (S/CO)	Antibody test
Hepatitis C Virus Genotype	Nucleic Acid Test (NAT)
Hepatitis C Virus RNA (PCR – Qualitative)	Nucleic Acid Test (NAT)
Hepatitis C Virus RNA (PCR – Quantitative)	Nucleic Acid Test (NAT)
Alanine Aminotransferase (ALT) <i>Serum glutamic pyruvic transaminase (SGPT)</i>	Liver function
Alkaline Phosphatase (Alk Phos)	Liver function
Aspartate Aminotransferase (AST) <i>Serum glutamic-oxaloacetic transaminase (SGOT)</i>	Liver function
Bilirubin Total – Bili (total)	Liver function

D. Local Health Department Letter Template

HCV Letter

{Local Health Department Letter}

Date

Patient Name

Patient Address

Dear Mr./Ms. X,

The _____ Health Department has made several attempts to contact you regarding a positive laboratory result that was received. New Jersey Administrative Code (NJAC 8:57) requires physicians, laboratories, and institutions (e.g., prisons, long term care, rehabilitation) to report certain communicable diseases to state and local health departments for follow up and investigation. Please contact our office at the phone number below so we may discuss this matter with you. If you are not aware of recent positive laboratory result, you may want to contact your healthcare provider prior to contacting our office.

Thank you,

_____ Health Department

Phone:

Fax:

Email: